Circulating tumour DNA—looking beyond the blood
Over the past decade, various liquid biopsy techniques have emerged as viable alternatives
to the analysis of traditional tissue biopsy samples. Such surrogate 'biopsies' offer numerous …
to the analysis of traditional tissue biopsy samples. Such surrogate 'biopsies' offer numerous …
Clinical relevance of blood-based ctDNA analysis: mutation detection and beyond
Cell-free DNA (cfDNA) derived from tumours is present in the plasma of cancer patients. The
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …
majority of currently available studies on the use of this circulating tumour DNA (ctDNA) deal …
Unravelling tumour heterogeneity by single-cell profiling of circulating tumour cells
Single-cell technologies have contributed to unravelling tumour heterogeneity, now
considered a hallmark of cancer and one of the main causes of tumour resistance to cancer …
considered a hallmark of cancer and one of the main causes of tumour resistance to cancer …
Life and death of circulating cell-free DNA
A Kustanovich, R Schwartz, T Peretz… - Cancer biology & …, 2019 - Taylor & Francis
Tumor-specific, circulating cell-free DNA in liquid biopsies is a promising source of
biomarkers for minimally invasive serial monitoring of treatment responses in cancer …
biomarkers for minimally invasive serial monitoring of treatment responses in cancer …
Current and future clinical applications of ctDNA in immuno-oncology
JC Stadler, Y Belloum, B Deitert, M Sementsov… - Cancer Research, 2022 - AACR
Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …
BRAF mutations in melanoma: biological aspects, therapeutic implications, and circulating biomarkers
G Castellani, M Buccarelli, MB Arasi, S Rossi… - Cancers, 2023 - mdpi.com
Simple Summary Cutaneous melanoma represents the most aggressive form of skin cancer
and its occurrence, development, and progression are based on the accumulation of several …
and its occurrence, development, and progression are based on the accumulation of several …
[HTML][HTML] Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA
Background The advent of effective adjuvant therapies for patients with resected melanoma
has highlighted the need to stratify patients based on risk of relapse given the cost and …
has highlighted the need to stratify patients based on risk of relapse given the cost and …
Early HPV ctDNA kinetics and imaging biomarkers predict therapeutic response in p16+ oropharyngeal squamous cell carcinoma
Y Cao, CT Haring, C Brummel, C Bhambhani… - Clinical Cancer …, 2022 - AACR
Purpose: In locally advanced p16+ oropharyngeal squamous cell carcinoma (OPSCC),(i) to
investigate kinetics of human papillomavirus (HPV) circulating tumor DNA (ctDNA) and …
investigate kinetics of human papillomavirus (HPV) circulating tumor DNA (ctDNA) and …
Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy
Background Treatment with anti-PD1 monoclonal antibodies improves the survival of
metastatic melanoma patients but only a subgroup of patients benefits from durable disease …
metastatic melanoma patients but only a subgroup of patients benefits from durable disease …
Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study
Background Melanoma lacks validated blood-based biomarkers for monitoring and
predicting treatment efficacy. Cell-free circulating tumour DNA (ctDNA) is a promising …
predicting treatment efficacy. Cell-free circulating tumour DNA (ctDNA) is a promising …